Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction

Vitamin D emerged as an important prognostic biomarker in heart failure (HF), with currently highly debated therapeutic implications. Several trials on vitamin D supplementation in HF showed improvements in left ventricular (LV) remodeling and function and health-related quality of life (HRQoL), whi...

Full description

Bibliographic Details
Main Authors:	Timea Magdolna Szabo, Előd Ernő Nagy, Ádám Kirchmaier, Erhard Heidenhoffer, Hunor-László Gábor-Kelemen, Marius Frăsineanu, Judit Cseke, Márta Germán-Salló, Attila Frigy
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Biomolecules
Subjects:	heart failure heart failure with reduced ejection fraction heart failure with mildly reduced ejection fraction vitamin D deficiency serum albumin serum uric acid
Online Access:	https://www.mdpi.com/2218-273X/13/11/1578

Similar Items

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-03-01)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
by: Mayu Tochiya, et al.
Published: (2023-04-01)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
by: Luigi Falco, et al.
Published: (2023-09-01)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
by: Tin‐Kwang Lin, et al.
Published: (2019-06-01)

Association of ambient temperature and acute heart failure with preserved and reduced ejection fraction
by: Takahiro Jimba, et al.
Published: (2022-10-01)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
by: Kaiyuan Zhu, et al.
Published: (2021-07-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction
by: Xin He, et al.
Published: (2021-08-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction
by: Liam Gaziano, et al.
Published: (2021-12-01)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
by: Federico Ferro, et al.
Published: (2022-07-01)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al.

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines
by: Luca Branca, et al.
Published: (2020-04-01)

Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort
by: Shiqun Chen, et al.
Published: (2022-08-01)

Personalized Target Heart Rate for Patients with Heart Failure and Reduced Ejection Fraction
by: Yusuke Yumita, et al.
Published: (2022-01-01)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022-10-01)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
by: Michele Senni, et al.
Published: (2022-12-01)

Prevalence and Long‐Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction
by: Louise Y. Sun, et al.
Published: (2018-06-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population
by: Son Kim Tran, et al.
Published: (2023-01-01)

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
by: Shunsuke Kiuchi, et al.
Published: (2020-02-01)

Is the obesity paradox in outpatients with heart failure reduced ejection fraction real?
by: Nathália Felix Araujo Salvino, et al.
Published: (2023-12-01)

Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments
by: Matthias Naegele, et al.
Published: (2016-02-01)

Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid‐range and preserved ejection fraction
by: Tomoya Ueda, et al.
Published: (2019-10-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction
by: Maria-Angela Moloce, et al.
Published: (2022-07-01)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2021-08-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers
by: Madelaire C, et al.
Published: (2020-06-01)

The Impact of Specialised Heart Failure Outpatient Care on the Long-Term Application of Guideline-Directed Medical Therapy and on Prognosis in Heart Failure with Reduced Ejection Fraction
by: Balázs Muk, et al.
Published: (2024-01-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
by: Raquel López‐Vilella, et al.
Published: (2022-02-01)

Cryoballoon ablation for atrial fibrillation in patients with heart failure with mildly reduced and preserved ejection fraction
by: Chaofeng Chen, et al.
Published: (2023-02-01)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
by: S. Heleen Binnenmars, et al.
Published: (2022-08-01)

Insulin Resistance Is Associated With Heart Failure With Recovered Ejection Fraction in Patients Without Diabetes
by: Chen Die Yang, et al.
Published: (2022-10-01)

Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension
by: Tran Kim Son, et al.
Published: (2022-05-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta‐analysis
by: Marta Leite, et al.
Published: (2023-06-01)